EUVIMEDEUVIMED entdecken
Systematische ÜbersichtÜbersichtsarbeit

A Systematic Review of the Specific Role of Biological Therapies in Aspirin-Exacerbated Respiratory Disease

Milagros Lázaro-Sastre, Esther Moreno-Rodilla, Cristina Martín-García, Juan Maza-Solano, María Gil-Melcon, Ignacio Dávila

Journal of Investigational Allergology and Clinical Immunology · 05.02.2026 · 36 (1) · 12-24

DOI: 10.18176/jiaci.1155 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Investigational Allergology and Clinical Immunology, online erschienen am 17.02.2026. Verfasst von Milagros Lázaro-Sastre und 5 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, University Hospital of Salamanca, Salamanca, Spain. Hauptthemen laut MEDLINE: Asthma, Aspirin-Induced, Biological Therapy, Aspirin, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aspirin-exacerbated respiratory disease (AERD) is characterized by chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs). Although high-dose aspirin therapy after desensitization (ATAD) and surgery are effective, adverse effects and high dropout rates limit its use. The emergence of biologics for asthma and/or CRSwNP entails rethinking the management of AERD. There is no consensus on choosing between ATAD and biologics. This systematic review evaluates current evidence on the role of biologics in the management of AERD, focusing on their potential to induce NSAID tolerance and proposing a management algorithm. A systematic literature search was conducted across PubMed, Embase, and Scopus up to March 2025. Studies were selected based on predefined criteria, excluding editorials, reviews, case reports, guidelines, and publications not in English. Data were extracted from clinical trials, real-world studies, and retrospective analyses. The various inflammatory pathways targeted by biologics included immunoglobulin E (omalizumab), subunit alpha of the interleukin 4 receptor (IL-4Ra) (dupilumab), IL-5/IL-5Ra (mepolizumab, benralizumab), and thymic stromal lymphopoietin (tezepelumab). These drugs have demonstrated efficacy in improving asthma and CRSwNP in AERD. The most consistent evidence seems to favor omalizumab and dupilumab for enhancing tolerance to NSAIDs. Although evidence remains inconclusive, the combination of ATAD and biologics may offer additive benefits in selected patients. Biologics represent a promising alternative in the management of AERD, particularly for patients with poor tolerance to aspirin. Further prospective, controlled studies are needed to define optimal treatment algorithms and identify biomarkers predictive of therapeutic response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Asthma, Aspirin-InducedBiological TherapyAspirinAnti-Inflammatory Agents, Non-SteroidalBiological ProductsHumansOmalizumabRhinosinusitisDesensitization, ImmunologicNasal PolypsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

ATADAspirin-exacerbated respiratory disease (AERD)Biological therapiesDesensitizationDupilumabMepolizumabNSAID hypersensitivityOmalizumab

Substanzen

AspirinAnti-Inflammatory Agents, Non-SteroidalBiological ProductsOmalizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Allergy Department, University Hospital of Salamanca, Salamanca, Spain.
  • Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain.
  • Inflammatory Diseases Network (REI), Institute of Health Carlos III, Madrid, Spain.
  • Rhinology and Skull Base Unit, Department of Otolaryngology, University Hospital Virgen Macarena, Sevilla, Spain.
  • Department of Surgery, University of Sevilla, Sevilla, Spain.

Zitieren

APA

Lázaro-Sastre, M., Moreno-Rodilla, E., Martín-García, C., Maza-Solano, J., Gil-Melcon, M., & Dávila, I. (2026). A Systematic Review of the Specific Role of Biological Therapies in Aspirin-Exacerbated Respiratory Disease. Journal of Investigational Allergology and Clinical Immunology, 36(1), 12-24. https://doi.org/10.18176/jiaci.1155

Vancouver

Lázaro-Sastre M, Moreno-Rodilla E, Martín-García C, Maza-Solano J, Gil-Melcon M, Dávila I. A Systematic Review of the Specific Role of Biological Therapies in Aspirin-Exacerbated Respiratory Disease. Journal of Investigational Allergology and Clinical Immunology. 2026;36(1):12-24. doi:10.18176/jiaci.1155

BibTeX
@article{LzaroSastre2026,
  author = {Lázaro-Sastre, Milagros and Moreno-Rodilla, Esther and Martín-García, Cristina and Maza-Solano, Juan and Gil-Melcon, María and Dávila, Ignacio},
  title = {A Systematic Review of the Specific Role of Biological Therapies in Aspirin-Exacerbated Respiratory Disease},
  journal = {Journal of Investigational Allergology and Clinical Immunology},
  year = {2026},
  volume = {36},
  number = {1},
  pages = {12--24},
  doi = {10.18176/jiaci.1155}
}
Kostenlos starten →